{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:52:15Z","timestamp":1770994335389,"version":"3.50.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","award":["06-547"],"award-info":[{"award-number":["06-547"]}],"id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","award":["033\/2007"],"award-info":[{"award-number":["033\/2007"]}],"id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0184065","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T13:42:22Z","timestamp":1504186942000},"page":"e0184065","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-6496","authenticated-orcid":true,"given":"Al\u00edcia Dorneles","family":"Dornelles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo","family":"Artigal\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Anjos","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora Lucia Vallejo","family":"Ardila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taciane","family":"Alegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Veiga","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo Pinto e","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Vanessa Doederlein","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"ref1","article-title":"The Online Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2014"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"PJ Meikle","year":"1999","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-3-24","article-title":"The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK","volume":"3","author":"D Moore","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","article-title":"Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry","volume":"118","author":"S Elliott","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"PV Hopkins","year":"2015","journal-title":"J Pediatr"},{"key":"ref6","unstructured":"2010. GT. Genzyme Therapeutics. Aldurazyme\u00ae (Laronidase). 2010 [cited 2016 13 November]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aldurazyme.com\" xlink:type=\"simple\">http:\/\/www.aldurazyme.com<\/ext-link>."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.12136","article-title":"Current and potential therapeutic strategies for mucopolysaccharidoses","volume":"39","author":"H Noh","year":"2014","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"ref8","first-page":"667","article-title":"Laronidase for treating mucopolysaccharidosis type I","volume":"6","author":"RP El Dib","year":"2007","journal-title":"Genet Mol Res"},{"key":"ref9","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme(\u00ae)) for treating mucopolysaccharidosis type I","volume":"4","author":"E Jameson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"JE Wraith","year":"2004","journal-title":"J Pediatr"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"LA Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s10545-006-0457-y","article-title":"Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome","volume":"29","author":"JA Thomas","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pediatrneurol.2012.08.010","article-title":"Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up","volume":"47","author":"A Jurecka","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"JE Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"ref15","unstructured":"Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011."},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"ED Kakkis","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"R Giugliani","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"M Sifuentes","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bjorl.2015.09.006","article-title":"The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis","volume":"82","author":"AP Dualibi","year":"2016","journal-title":"Braz J Otorhinolaryngol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9444-z","article-title":"Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI","volume":"36","author":"MM Brands","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","article-title":"Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients","volume":"33","author":"A Tylki-Szymanska","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"JP Higgins","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jrsm.13","article-title":"Critical interpretation of Cochran&apos;s Q test depends on power and prior assumptions about heterogeneity","volume":"1","author":"TV Pereira","year":"2010","journal-title":"Res Synth Method"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"H Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"ref26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"GH Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Y Xue","year":"2016","journal-title":"Mol Genet Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"JA Sterne","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S1415-47572014000100006","article-title":"Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network","volume":"37","author":"AD Dornelles","year":"2014","journal-title":"Genet Mol Biol"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jrsm.13","article-title":"Critical interpretation of Cochran&apos;s Q test depends on power and prior assumptions about heterogeneity","volume":"1","author":"TV Pereira","year":"2010","journal-title":"Res Synth Methods"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"e69930","DOI":"10.1371\/journal.pone.0069930","article-title":"A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses","volume":"8","author":"E Kontopantelis","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2017.04.004","article-title":"Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis","volume":"121","author":"J P\u00e9rez-L\u00f3pez","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-016-0437-8","article-title":"Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series","volume":"11","author":"DD Horovitz","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"ref34","first-page":"S157","article-title":"Cardiac evaluation in mucopolysaccharidosis patients undergoing enzyme replacement therapy","volume":"33","author":"Hagemans MLC Brands MMMG","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ymgme.2010.11.121","article-title":"Update on the longitudinal study of bone and endocrine disease in children with MPS I, II, and VI","volume":"102","author":"L Polgreen","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref36","first-page":"S207","article-title":"Effects of enzyme replacement therapy (ERT) on joint mobility in 27 patients(PTS) with mucopolysaccharidosis (MPS) I, II and VI","volume":"34","author":"F Furlan","year":"2011","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vhri.2015.08.002","article-title":"Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study","volume":"8","author":"Vieira TA Bitencourt FHd","year":"2015","journal-title":"Value in Health Regional Issues"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up","volume":"125","author":"O Gabrielli","year":"2010","journal-title":"Pediatrics"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12881-016-0284-4","article-title":"12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment","volume":"17","author":"O Gabrielli","year":"2016","journal-title":"BMC Med Genet"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","article-title":"Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships","volume":"10","author":"NA Al-Sannaa","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"39","key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"K Wyatt","year":"2012","journal-title":"Health Technol Assess"},{"issue":"1","key":"ref42","article-title":"A terapia de reposi\u00e7\u00e3o enzim\u00e1tica pode mudar a frequ\u00eancia de interven\u00e7\u00f5es m\u00e9dicas na mucopolissacaridose tipo I? Um estudo retrospectivo e explorat\u00f3rio [Can enzyme replacement therapy change the frequency of medical interventions in mucopolysacchari\u2026]","volume":"34","author":"FH de Bitencourt","year":"2014"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0184065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:10:24Z","timestamp":1540339824000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0184065"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Dardis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0184065","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}